Clinical Research Directory

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

Sponsor: Verve Therapeutics, Inc.

Summary

The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.

Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of VERVE-102, a One-Time Dose Gene Editing Medicine, in Adults With or at High Risk for Atherosclerotic Cardiovascular Disease (ASCVD) Who Require Additional Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering

Key Details

Conditions

Interventions

Locations (1)